11:18:37 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Halvårsutdelning VISTN 0.5
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-05 Halvårsutdelning VISTN 0.5
2024-05-23 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2024-01-23 Ordinarie utdelning VISTN 0.75 NOK
2023-10-25 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-23 Ordinarie utdelning VISTN 0.00 NOK
2023-05-22 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-24 Ordinarie utdelning VISTN 0.00 NOK
2022-05-19 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning VISTN 0.50 NOK
2021-05-20 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-06-24 Extra Bolagsstämma 2020
2020-05-20 Ordinarie utdelning VISTN 1.00 NOK
2020-05-19 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning VISTN 0.00 NOK
2019-05-22 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-19 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning VISTN 1.00 NOK
2018-05-08 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-03 Bonusutdelning VISTN 7
2017-11-02 Extra Bolagsstämma 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning VISTN 1.00 NOK
2017-05-24 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-05-25 Ordinarie utdelning VISTN 0.60 NOK
2016-05-24 Årsstämma 2016
2016-04-28 Kvartalsrapport 2016-Q1
2016-02-23 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Idag innehas verksamhet på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades under 2015 och har sitt huvudkontor i Oslo.
2022-12-09 12:10:00

Oslo, Norway, 9 December 2022

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) announces that it has entered into a long-term industrial energy agreement with Statkraft, the leading Norwegian energy supplier. The agreement will secure a significant part of Vistin’s electricity demand on competitive terms until 2032. The agreement includes Guarantees of Origin as certification of the renewable energy supply, and starts 1.1.2023.

2022 has been very challenging for Vistin and the Norwegian industry, when it comes to electricity costs, with extreme volatility and record high electricity prices in the NO2 area where Vistin’s fully automated production plant is located.

- This agreement will give Vistin Pharma stable electricity supply at predictable and competitive prices. The agreement helps to secure our competitiveness in the global Metformin market. We are happy that Statkraft by this agreement contributes to the future development of Vistin and thereby allows the company to continue focusing on its growth strategy, says Kjell-Erik Nordby, CEO in Vistin Pharma.

- We are very pleased to conclude another renewable energy contract with the Norwegian industry which confirms that Statkraft offers relevant solutions at competitive terms, says Frode Berntsen, Head of Industry Nordics & Baltics at Statkraft.  

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.

About Statkraft | www.statkraft.com

Statkraft is a leading company in hydropower internationally and Europe's largest generator of renewable energy. The Group produces hydropower, wind power, solar power, gas-fired power and supplies district heating. Statkraft is a global company in energy market operations Statkraft has 4,800 employees in 20 countries.

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com